Service by

Home Journal Issues Guide for Authors Editorial Board About Aims & Scope Editorial Contact


Original Research Open Access


Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51

Ahmed M A Mansour.

Abstract
Background: Brucella abortus strain RB51 is a rough strain that was derived after multiple passages of virulent strain 2308. Levamisole, a potent anthelmintic that is widely used in veterinary medicine, is also known as an immune stimulant.

Aim and Objectives: Determine the capability of levamisole to enhance the humoral antibody response and cell-mediated immunity as well as protective capacity of RB51 vaccine in mice against challenge with virulent Brucella melitensis strain.

Materials and Methods: Six groups of 78-week-old female Bulb/C mice were used. Group I was vaccinated I/P with 5 108 colony-forming units (CFU) of RB51 strain. Group II was vaccinated I/P with 5 108 CFU of RB51 strain simultaneously injected (at 0 day) s/cu with 12.5 mg/Kg levamisole. Group III was vaccinated I/P with 5 108 CFU of RB51 strain and injected at 7-day postvaccination with 12.5 mg/Kg levamisole. Group IV was vaccinated I/P with 5 108 CFU of RB51 strain and injected at the day of vaccination (0 day) and 7-day postvaccination with 12.5 mg/Kg levamisole. Group V was injected with levamisole alone. Group VI was kept as control group. 8-week postvaccination; all vaccinated as well as control animals groups received I/P challenge of 2 ml dose of 2 104 CFU/ml of virulent strain of B. melitensis biovar 3.

Results: (Groups III and IV) At the day of vaccination (0 day) and 7-day postvaccination showed the highest significant serum antibody titer measured by ELISA all over the experimental period as well as increase in delayed type hypersensitivity (DTH) response 48 h after elicitation by intradermal inoculation of B. abortus soluble antigen compared to vaccinated control group (Group I). While RB51 vaccinated and simultaneously treated with levamisole (Group II) showed mild elevation in antibody titer as well as the lowest significant increase in DTH response compared to vaccinated control group. Bioassay test of challenged mice groups showed significant improvement in the resistance of vaccinated groups treated with levamisole either 7-day post-vaccination (Group III) or 0 and 7 days postvaccination (Group IV) which showed 10% bacteriologically positive mice, whereas only 30% of the vaccinated control mice (Group I) and vaccinated simultaneously treated with levamisole (Group II), were bacteriologically positive.

Key words: Levamisole; Brucella; Immunogenic Capacity; Protective Capacity; RB51


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Ahmed M A Mansour
on Google
on Google Scholar
Article Statistics
 Viewed: 35
Downloaded: 17
Cited: 0


How to Cite this Article
Pubmed Style

Ahmed M A Mansour. Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51. doi:10.5455/njppp.2018.8.1143004122017


Web Style

Ahmed M A Mansour. Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51. http://www.njppp.com/?mno=282607 [Access: January 24, 2018]. doi:10.5455/njppp.2018.8.1143004122017


AMA (American Medical Association) Style

Ahmed M A Mansour. Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51. doi:10.5455/njppp.2018.8.1143004122017



Vancouver/ICMJE Style

Ahmed M A Mansour. Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51. doi:10.5455/njppp.2018.8.1143004122017



Harvard Style

Ahmed M A Mansour (2018) Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51. doi:10.5455/njppp.2018.8.1143004122017



Turabian Style

Ahmed M A Mansour. 2018. Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51. doi:10.5455/njppp.2018.8.1143004122017



Chicago Style

Ahmed M A Mansour. "Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51." doi:10.5455/njppp.2018.8.1143004122017



MLA (The Modern Language Association) Style

Ahmed M A Mansour. "Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51." doi:10.5455/njppp.2018.8.1143004122017



APA (American Psychological Association) Style

Ahmed M A Mansour (2018) Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51. doi:10.5455/njppp.2018.8.1143004122017



AUTHOR LOGIN

REVIEWER LOGIN

Indexed In

 

National Journal of Physiology, Pharmacy and Pharmacology is Indexed in -

EMBASE

Index Copernicus  (ICV 2016: 109)

Index Medicus for SEAR

CAB abstract/Global Health

CINAHL

Hinari

Google Scholar

ScopeMed

Ulrich’s International Periodical Directory

Indian Science Abstracts

Open J- Gate

Geneva Foundation for Medical Education and Research

NewJour

PSOAR

InformIndia

EBSCO Publishing Electronic Database

Genamics JournalSeek

ProQuest

Index Scholar

SafetyLit

Chemical Abstracts Service (CAS)

Gale's Health Reference Center

Gale Info Trac

Gale Academic Onefile

Ind Medica

Scirus

Scientific Publication Index

Scientific Resources Database

Recent Science Index

Scholarly Journals Index

Directory of Academic Resources

Elite Scientific Journals Archives

Current Index to Scholarly Journals

Digital Journals Database

Academic Papers Database

Contemporary Research Index

Ayush Web Portal

CiteFactor

 

 

 

 

 

 

Journal Membership

World Association of Medical Editors (WAME), Dallas, Texas, USA

 

Journal Listed in

ICMJE- International Committee of Medical Journal Editors

HIFA 2015 – Healthcare Information for All by 2015, Charlbury, Oxfordshire, UK 

 

 


The articles in this Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.